Bolt Biotherapeutics Stock Probability of Future Stock Price Finishing Over 0.5786
| BOLT Stock | USD 0.58 0.01 1.51% |
Bolt |
Bolt Biotherapeutics Target Price Odds to finish over 0.5786
The tendency of Bolt Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.58 | 90 days | 0.58 | roughly 97.0 |
Based on a normal probability distribution, the odds of Bolt Biotherapeutics to move above the current price in 90 days from now is roughly 97.0 (This Bolt Biotherapeutics probability density function shows the probability of Bolt Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Bolt Biotherapeutics has a beta of 0.0347 suggesting as returns on the market go up, Bolt Biotherapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Bolt Biotherapeutics will be expected to be much smaller as well. Additionally Bolt Biotherapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Bolt Biotherapeutics Price Density |
| Price |
Predictive Modules for Bolt Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bolt Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Bolt Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bolt Biotherapeutics is not an exception. The market had few large corrections towards the Bolt Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bolt Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bolt Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.27 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | -0.15 |
Bolt Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bolt Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bolt Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bolt Biotherapeutics generated a negative expected return over the last 90 days | |
| Bolt Biotherapeutics has some characteristics of a very speculative penny stock | |
| Bolt Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.88 M. Net Loss for the year was (69.2 M) with profit before overhead, payroll, taxes, and interest of 1.62 M. | |
| Bolt Biotherapeutics currently holds about 176.34 M in cash with (69.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bolt Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 44000 shares by Sarah Nemec of Bolt Biotherapeutics at 3.08 subject to Rule 16b-3 |
Bolt Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bolt Stock often depends not only on the future outlook of the current and potential Bolt Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bolt Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 37.8 M | |
| Cash And Short Term Investments | 102.2 M |
Bolt Biotherapeutics Technical Analysis
Bolt Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Bolt Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Bolt Biotherapeutics. In general, you should focus on analyzing Bolt Stock price patterns and their correlations with different microeconomic environments and drivers.
Bolt Biotherapeutics Predictive Forecast Models
Bolt Biotherapeutics' time-series forecasting models is one of many Bolt Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Bolt Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Bolt Biotherapeutics
Checking the ongoing alerts about Bolt Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bolt Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Bolt Biotherapeutics generated a negative expected return over the last 90 days | |
| Bolt Biotherapeutics has some characteristics of a very speculative penny stock | |
| Bolt Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.88 M. Net Loss for the year was (69.2 M) with profit before overhead, payroll, taxes, and interest of 1.62 M. | |
| Bolt Biotherapeutics currently holds about 176.34 M in cash with (69.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bolt Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 44000 shares by Sarah Nemec of Bolt Biotherapeutics at 3.08 subject to Rule 16b-3 |
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.